Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity Biosciences Inc. (NASDAQ:RNA) adjourned its special stockholder meeting scheduled for the same day and moved the date to February 26. Avidity Biosciences Inc. (NASDAQ:RNA) said it needs additional time to satisfy conditions for the distribution of all outstanding shares of Atrium Therapeutics Inc. to Avidity stockhol ...

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies [Accessibility Statement] Skip NavigationSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platformLead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ...

Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Av ...

业务进展情况 研发管线关键里程碑：诺华正处于密集的研发周期，2026年预计将有7项关键数据读出，未来两年内可 能有超过15项潜在上市申报或关键数据读出，涉及30多个高价值管线资产。具体而言，公司预告2026年 将有28项监管申请递交或批准、9项重要研究读出数据以及6项关键研究启动。这些事件覆盖心血管、肿 瘤、免疫和神经科学等领域。 战略推进 并购与业务拓展活动：诺华首席执行官万思瀚强调，公司将继续通过单笔金额不超过20亿美元的早期交 易充实研发管线，同时积极寻找后期阶段资产，尤其是未来五年内有望上市的品种。近期案例包括对 Avidity、Tourmaline等公司的收购，这类交易可能持续影响管线布局。 近期公司状况 经济观察网 基于2026年2月发布的诺华最新财报和战略展望，以下是诺华制药股票在2026年及近期可能 值得关注的事件摘要。这些信息主要来源于公司官方公告和财经媒体报道。 近期事件 2026年财务业绩与股息计划：诺华管理层在2026年战略展望中预计，全年净销售额将实现低个位数增 长，但核心营业收入可能下降低个位数。公司计划在2026年派发每股3.70瑞士法郎的股息，按瑞士法郎 计算同比增长。首席财务 ...

Core Insights - Novartis AG reported fourth-quarter core earnings per share of $2.03, exceeding the Zacks Consensus Estimate of $1.99 and up from $1.98 a year ago [1][7] - Core net income decreased by 1% to $3.9 billion, while revenues of $13.3 billion fell short of the Zacks Consensus Estimate of $13.7 billion, despite a 1% year-over-year increase [2][7] - The company faced revenue pressure from generic competition for key drugs Entresto and Promacta, leading to a 1% decline in sales on a constant currency basis [2][26] Financial Performance - Core operating income improved by 1% to $4.9 billion, supported by higher government grant income and lower SG&A expenses, although offset by increased R&D expenses [19] - For 2025, Novartis reported sales growth of 8% to $54.53 billion, surpassing the Zacks Consensus Estimate, with core EPS increasing by 17% to $8.98 [20] - Guidance for 2026 indicates low single-digit growth in net sales on a constant currency basis, with core operating income expected to decline in low single digits [21] Drug Performance - Cosentyx sales rose 11% to $1.8 billion, driven by strong demand across all regions [5] - Kisqali sales surged 44% to $1.32 billion, although it missed estimates, with underlying global growth at 54% [6][8] - Entresto sales plummeted 45% to $1.2 billion due to generic competition, while Promacta sales fell 63% to $226 million [8][13] - Pluvicto sales increased by 70% to $605 million, driven by strong demand following recent approvals [11] - Kesimpta sales grew 27% to $1.2 billion, while Jakavi sales increased by 8% to $555 million [10][12] Strategic Updates - Novartis announced plans to acquire Avidity Biosciences for $12 billion to enhance its late-stage neuroscience pipeline [22][23] - The acquisition aims to strengthen the company's position in addressing genetic neuromuscular diseases [28] - A collaboration agreement with the U.S. government was established to reduce drug prices while supporting ongoing investments in manufacturing and R&D [25] Market Position - Novartis shares have gained 42.1% over the past year, outperforming the industry growth of 19% [2] - The company is navigating significant patent expirations, with a focus on key growth drivers such as Kisqali, Kesimpta, Pluvicto, and Scemblix [26][27]

Core Insights - Novartis reported strong performance in 2025 with high single-digit sales growth and core margin expansion despite facing significant US generic competition [3] - Key growth drivers included Kisqali, Kesimpta, Pluvicto, Scemblix, and Cosentyx, which continued their strong trajectory [3] - The company advanced several potential multi-blockbusters in its pipeline with FDA approvals and positive Phase III readouts [3] - Novartis expects to grow through the largest patent expiry in its history in 2026, indicating the strength of its business [3] Financial Performance - Q4 2025 net sales reached USD 13.3 billion, a 1% increase year-over-year, while full-year net sales were USD 54.5 billion, reflecting an 8% increase [4][13] - Operating income for Q4 was USD 3.6 billion, up 2%, and for the full year, it was USD 17.6 billion, a 21% increase [10][13] - Net income for Q4 was USD 2.4 billion, down 15%, while full-year net income was USD 14.0 billion, up 17% [10][14] - Core operating income for Q4 was USD 4.9 billion, a 1% increase, and for the full year, it was USD 21.9 billion, a 12% increase [11][16] - Free cash flow for Q4 was USD 1.7 billion, down 54%, while for the full year, it was USD 17.6 billion, an 8% increase [12][17] Key Growth Drivers - Priority brands showed strong performance in Q4, with Kisqali sales growing 44%, Kesimpta 27%, Pluvicto 70%, Scemblix 87%, and Cosentyx 11% [18] - The top 20 brands contributed to a total of USD 10.8 billion in Q4 sales, with a slight increase of 2% year-over-year [19] R&D and Innovation - Novartis received FDA approval for Itvisma, the first gene replacement therapy for a broad SMA population, and expanded indications for Scemblix [21] - Pluvicto's FDA submission for metastatic hormone-sensitive prostate cancer was completed based on Phase III data [22] - Ongoing trials for ianalumab showed significant benefits in Sjögren's disease and primary immune thrombocytopenia [23][24] Strategic Initiatives - Novartis announced a proposed acquisition of Avidity Biosciences, expected to close in the first half of 2026, enhancing its pipeline in neuroscience [25] - The company reached an agreement with the US government to lower drug prices, which will impact its 2026 guidance [32] Capital Structure - Novartis repurchased 77.6 million shares for USD 8.9 billion in 2025, reducing the total number of shares outstanding by 66.9 million [27] - Net debt increased to USD 21.9 billion by the end of 2025, primarily due to cash outflows for share repurchases and dividends [28] 2026 Guidance - For 2026, Novartis expects low single-digit growth in net sales and a decline in core operating income [30]

Core Insights - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1] - The firm is currently investigating multiple companies related to their proposed sales, including The Brand House Collective, Avidity Biosciences, NorthWestern Energy Group, and Two Harbors Investment Corp [1][2][3][4] Company Investigations - The Brand House Collective, Inc. (NASDAQ: TBHC) is set to be sold to Bed Bath & Beyond, Inc., with shareholders expected to receive 0.1993 shares of Bed Bath & Beyond for each share of Brand House [1] - Avidity Biosciences, Inc. (NASDAQ: RNA) is proposed to be sold to Novartis AG, with shareholders receiving $72.00 per share in cash [2] - NorthWestern Energy Group, Inc. (NASDAQ: NWE) is being sold to Black Hills Corp, where shareholders will receive 0.98 shares of Black Hills for each share of NorthWestern, resulting in approximately 44% ownership of the combined company for NorthWestern shareholders [3] - Two Harbors Investment Corp. (NYSE: TWO) is proposed to be sold to UWM Holdings Corporation, with shareholders receiving 2.3328 shares of UWM Class A common stock for each share of Two Harbors [4] Shareholder Votes - The shareholder vote for The Brand House Collective is scheduled for March 17, 2026 [2] - The shareholder vote for Avidity Biosciences is scheduled for February 23, 2026 [3] - The shareholder vote for NorthWestern Energy Group is scheduled for April 2, 2026 [4]

Investment Rating - The report indicates a positive outlook for European M&A activity, expecting continued momentum into 2026, with a strong case for consolidation across various sectors [3][4][6]. Core Insights - European M&A deal value increased by 12% in 2025, reaching approximately $820 billion, driven by a shift in investor asset allocation towards Europe [3]. - Corporate profitability in Europe has risen by 50% from pre-2008 levels, yet many companies remain sub-scale, indicating a strong need for acquisitions to build capabilities [5]. - A robust pipeline of announced but uncompleted deals, along with favorable capital availability and regulatory conditions, suggests sustained M&A activity in 2026 [6]. Summary by Relevant Sections 1. Banking Sector - European banking M&A has seen a doubling in deal volumes since 2020, driven by restored profitability and regulatory support for consolidation [13]. - Banks are expected to generate over $500 billion in excess capital above regulatory minima over the next three years, which will be increasingly deployed in M&A [15]. 2. Asset Management - The asset and wealth management sector is facing consolidation due to profit margin pressures, with predictions of a 20% reduction in the number of asset managers by 2030 [17]. - M&A activity is expected to intensify, with 100 to 200 transactions anticipated annually in Europe [19]. 3. Telecommunications - The European telecom market is maturing, necessitating M&A for value-accretive deals amid high investment needs for 5G and fiber [20]. - The average EU operator has about 5 million subscribers, compared to 107 million in the US, highlighting the need for consolidation [20]. 4. Defense Sector - Military spending in Europe is projected to grow at approximately 9% annually through 2030, leading to increased demand for production capabilities [23]. - M&A is shifting towards acquiring production capabilities, with a focus on modernizing technical advantages [25]. 5. Logistics - The logistics sector is prioritizing transformative M&A strategies to address e-commerce growth and traditional mail network contraction [28]. - Acquirers are focusing on contract logistics and technology capabilities as core to deal value capture [31]. 6. Pharmaceuticals - Pharma dealmaking is becoming essential as companies face patent expirations and pipeline gaps, with a focus on high-value assets [33]. - Transaction activity is expected to be dominated by selective, de-risked acquisitions and structured deals to manage valuation risks [36]. 7. Chemicals - The chemical industry is leveraging M&A to refocus portfolios on specialty segments and secure cash flow amid economic challenges [37]. - Larger transactions are aimed at building global platforms and enhancing sustainability efforts [39]. 8. Insurance - M&A activity in the insurance sector is driven by private equity consolidation, accounting for about 90% of transactions by volume [42]. - The report anticipates continued acquisitions of specialty underwriting franchises by strategic buyers [45]. 9. Private Equity - European corporates hold approximately €2.6 trillion in cash, creating opportunities for trade buyers of private equity-backed assets [48]. - In 2026, over 1,500 European PE-backed assets, representing $760 billion in enterprise value, could potentially come to market [49]. 10. Portfolio Rebalancing - Portfolio rebalancing is becoming a core theme in European M&A as companies respond to economic headwinds and high capital costs [56]. - One-third of European corporates deliver returns below their cost of capital, indicating a need for divestitures of non-core assets [56].

Core Insights - Immunocore Holdings PLC's stock price increased by 5.9% to $35.29, following a period of 7.9% loss over the past four weeks, indicating a significant recovery in trading volume [1] - The company's strategic priorities for 2026 focus on commercial expansion of its drug KIMMTRAK and advancements in clinical studies, including late-stage melanoma studies and new data on early-stage cancer and HIV [2] - The upcoming quarterly report is expected to show a loss of $0.28 per share, a 40.4% improvement year-over-year, with revenues projected at $107.83 million, reflecting a 28.3% increase from the previous year [3] - The consensus EPS estimate for the quarter has been revised 13% higher in the last 30 days, suggesting a positive trend that may lead to further stock price appreciation [4] - Immunocore holds a Zacks Rank of 1 (Strong Buy), indicating strong market confidence, while Avidity Biosciences, a peer in the same industry, has a lower Zacks Rank of 3 (Hold) [5][6] Company Performance - Immunocore's stock performance is bolstered by its strategic focus and positive earnings estimate revisions, which historically correlate with stock price movements [3][4] - The anticipated revenue growth and improved EPS estimates position Immunocore favorably within the biomedical and genetics industry [2][3] Industry Context - Immunocore is part of the Zacks Medical - Biomedical and Genetics industry, where it competes with companies like Avidity Biosciences, which has seen a negative revision in its EPS estimates [5][6]

Group 1: Overview of Mergers and Acquisitions - The fourth quarter of 2025 saw a surge in global mergers and acquisitions, with significant deals exceeding $40 billion in sectors such as media, entertainment, data centers, and consumer goods [1] - A total of ten representative large-scale mergers and acquisitions were highlighted, providing insights into the trends and activities in the market [1] Group 2: Notable Mergers and Acquisitions - A consortium led by BlackRock, Nvidia, and Microsoft is set to acquire Aligned DataCenters for approximately $40 billion, aiming to expand next-generation cloud and AI infrastructure [2] - Airbus, Leonardo, and Thales signed a memorandum to merge their space businesses into a new company expected to generate annual revenues of about €6.5 billion, with a workforce of 25,000 in Europe [4] - Novartis agreed to acquire Avidity Biosciences for around $12 billion to enhance its portfolio for rare muscle diseases [7] - Kimberly-Clark will acquire Kenvue for approximately $48.7 billion, creating a major consumer health products company with projected annual net revenues of about $32 billion by 2025 [9] - Pfizer has successfully acquired Metsera, a weight-loss drug startup, in a deal valued at over $10 billion [10] - AkzoNobel plans to merge with Axalta Coating Systems, resulting in a combined company valued at $25 billion, with expected annual revenues of $17 billion [12] - Abbott Laboratories is acquiring Exact Sciences for $23 billion, marking its largest acquisition in nearly a decade [13] - Netflix agreed to acquire Warner Bros. Discovery's TV and film production and streaming assets for an enterprise value of $82.7 billion [14] - IBM will acquire Confluent for $11 billion to strengthen its cloud computing offerings [17] - ByteDance has established a new joint venture in the U.S. for TikTok, with a consortium of investors holding 50% of the shares [20] Group 3: Completed Mergers and Acquisitions - Lowe's completed its acquisition of Foundation Building Materials, marking its largest acquisition to date [21] - Omnicom Group's acquisition of Interpublic Group was approved by the EU, making it the largest marketing communications group globally with revenues exceeding $25 billion [21] - Mars Incorporated completed its acquisition of Kellanova for a total consideration of $35.9 billion [21] - XRG completed its acquisition of Covestro, marking a significant step in its goal to become one of the top three chemical investment companies globally [22] - Boeing and Airbus completed their acquisition of Spirit AeroSystems' assets, integrating thousands of employees into their operations [22] - Geely Automobile announced its merger with Zeekr, with a total consideration of approximately $2.399 billion [23] Group 4: Failed Mergers and Acquisitions - BHP Group abandoned its acquisition proposal for Anglo American, focusing on its existing asset portfolio [25] - Performance Food and US Foods terminated their merger discussions, which would have created a significant competitor in the food distribution industry [25]